Pharma major Lupin Ltd on Thursday said it has launched its generic version of Prucalopride tablets used to treat chronic idiopathic constipation in the US market after the recent approval by the country's health regulatory.
The Mumbai-based company has launched Prucalopride tablets of strengths 1 mg, and 2 mg in the US, following the recent approval of its abbreviated new drug application (ANDA) from the USFDA, Lupin said in a regulatory filing.
These Prucalopride tablets are bioequivalent to Motegrity tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc and are indicated for the treatment of chronic idiopathic constipation (CIC) in adults, it added.
Citing IQVIA MAT April 2025 data, the company said Prucalopride tablets, 1 mg and 2 mg, had estimated annual sales of USD 184 million in the US.
The Mumbai-based company has launched Prucalopride tablets of strengths 1 mg, and 2 mg in the US, following the recent approval of its abbreviated new drug application (ANDA) from the USFDA, Lupin said in a regulatory filing.
These Prucalopride tablets are bioequivalent to Motegrity tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc and are indicated for the treatment of chronic idiopathic constipation (CIC) in adults, it added.
Citing IQVIA MAT April 2025 data, the company said Prucalopride tablets, 1 mg and 2 mg, had estimated annual sales of USD 184 million in the US.
You may also like
Cocky conman who scammed five-star hotels with fake tea plot jailed after web of lies
Paul Mullin says he's still in the dark over Wrexham exile as truth over Wigan move emerges
One bathroom act is helping scientists create 'silent killer' early warning
Navy staffer held for leaking Operation Sindoor details, other classified info to Pakistani handler
School uniform grants: How thousands of parents can get £200 free cash help
